Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial()

BACKGROUND: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-ri...

Descripción completa

Detalles Bibliográficos
Autores principales: McMillan, A.K., Phillips, E.H., Kirkwood, A.A., Barrans, S., Burton, C., Rule, S., Patmore, R., Pettengell, R., Ardeshna, K.M., Lawrie, A., Montoto, S., Paneesha, S., Clifton-Hadley, L., Linch, D.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487775/
https://www.ncbi.nlm.nih.gov/pubmed/32464282
http://dx.doi.org/10.1016/j.annonc.2020.05.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487775/
https://www.ncbi.nlm.nih.gov/pubmed/32464282
http://dx.doi.org/10.1016/j.annonc.2020.05.016

Ejemplares similares